Results 151 to 160 of about 5,315 (239)

Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST‐3 study design

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Aims Lifestyle modification, including caloric restriction and exercise, is fundamental in the treatment of people living with overweight and type 2 diabetes mellitus (T2D). The overall aim of lifestyle intervention schemes is to reduce body weight and improve glycaemic control to reduce the future risk of diabetes‐associated complications ...
Caren Sourij, Alexander Müller, Abdullah Al‐Baghdadi, Faisal Aziz, Norbert J. Tripolt, Peter N. Pferschy, Eva Andritz, Harald Kojzar, Vanessa Stadlbauer, Sabrina Leal Garcia, Harald Sourij   +10 more
wiley   +1 more source

Combined In Vitro and Computational Investigations on Synthesized Sulfonamide-Based Antidiabetic Agents. [PDF]

Pharmaceuticals (Basel)
Iacob AD, Cioancă O, Aprodu I, Tatia R, Iacob AT, Mircea C, Tutunaru D, Pavel AB, Lungu II, Dragostin OM.   +9 more
europepmc   +1 more source

A systematic review and meta‐analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction Achieving and sustaining target glycated haemoglobin (HbA1c) levels is fundamental in the management of type 2 diabetes (T2D). We here aimed to assess whether initial dual oral therapy outperforms monotherapy in reaching glycaemic targets in patients with treatment‐naive or early‐stage T2D.
Mairead Kelly, Sushant Saluja, Hugh Logan Ellis, Sarah Jamil, Martin B. Whyte, Adrian Heald   +5 more
wiley   +1 more source

Effect of antidiabetic medication adherence on risk of all-cause mortality and cardiovascular diseases in type 2 diabetes patients: Impact of antidiabetic adherence on cardiovascular disease. [PDF]

Medicine (Baltimore)
Seo DH, Ha KH, Kim SH, Kim DJ.
europepmc   +1 more source

Cost‐Effectiveness of Control‐IQ+ Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6280-6290, July 2026.
ABSTRACT Objective Automated insulin delivery (AID) has been established as an effective therapy for individuals with type 1 diabetes. This analysis evaluates the clinical and economic outcomes of AID compared with multiple daily injections plus continuous glucose monitoring (MDI/CGM) in adults with type 2 diabetes. Materials and Methods The IQVIA CORE
Neda Al Rawashdh, Bimal V. Patel, Sharon M. Wang, Richard M. Zur, Pablo Anaya, Emily B. Kahn, Jordan E. Pinsker, Ravid Sasson‐Katchalski, Alex C. Trahan, Laurel H. Messer, Kimia Assadi, Yogish C. Kudva, Roy W. Beck   +12 more
wiley   +1 more source

Sarcopenia and chronic pain: Identification of shared genetic determinants and therapeutic implication. [PDF]

Medicine (Baltimore)
Li J, Huang J, Han J.
europepmc   +1 more source

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5740-5750, July 2026.
ABSTRACT Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common.
Christine Ljungberg, Mette Nørgaard, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Reimar Wernich Thomsen   +5 more
wiley   +1 more source

Blood Pressure Status Modulates the Therapeutic Response to Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Macular Edema: A Post Hoc Subgroup Analysis of the COMET Trial. [PDF]

J Diabetes
Ishibashi R, Koshizaka M, Takatsuna Y, Tatsumi T, Baba T, Yamamoto S, Yokote K.   +6 more
europepmc   +1 more source

Partial restoration of counterregulatory circulating glucagon by dapagliflozin and low-dose glibenclamide in men with type 1 diabetes: in vitro studies and randomised clinical crossover trial. [PDF]

EBioMedicine
Gao R, Spiliotis I, Dou H, Hill TG, Kothegala L, Miranda C, Abiakam N, Coleman RL, White S, Adler A, Rorsman P.   +10 more
europepmc   +1 more source

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5834-5847, July 2026.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Shao‐Chia Chen, Hao‐I Hsieh, Gideon Meyerowitz‐Katz, Yen‐Liang Liu, Pen‐Hua Su   +8 more
wiley   +1 more source